Health Care & Life Sciences » Pharmaceuticals | BLIS Technologies Ltd.

BLIS Technologies Ltd. | Income Statement

Fiscal year is April-March. All values NZD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
1,263.00
2,523.00
5,628.00
6,543.00
5,285.00
8,113
Cost of Goods Sold (COGS) incl. D&A
1,718.00
3,322.00
5,813.00
5,848.00
5,433.00
4,904
Gross Income
455.00
799.00
185.00
695.00
148.00
3,209
SG&A Expense
702.00
682.00
664.00
319.00
889.00
3,099
EBIT
1,600.00
1,481.00
849.00
376.00
1,037.00
110
Unusual Expense
-
-
-
7.00
-
-
Non Operating Income/Expense
-
-
-
397.00
-
287
Interest Expense
-
-
-
-
8.00
22
Pretax Income
1,541.00
1,373.00
816.00
24.00
1,042.00
381
Consolidated Net Income
1,541.00
1,373.00
816.00
24.00
1,042.00
381
Net Income
1,541.00
1,373.00
816.00
24.00
1,042.00
381
Net Income After Extraordinaries
1,541.00
1,373.00
816.00
24.00
1,042.00
381
Net Income Available to Common
1,541.00
1,373.00
816.00
24.00
1,042.00
381
EPS (Basic)
0.00
0.00
0.00
-
0.00
-
Basic Shares Outstanding
892,953.10
1,102,153.60
1,102,153.60
1,106,704.30
1,107,653.60
1,107,653.60
EPS (Diluted)
0.00
0.00
0.00
0.00
0.00
-
Diluted Shares Outstanding
892,953.10
1,102,153.60
1,102,153.60
1,106,704.30
1,107,653.60
1,107,653.60
EBITDA
1,108.00
922.00
293.00
985.00
427.00
635
Other Operating Expense
443.00
-
-
-
-
-
Non-Operating Interest Income
59.00
108.00
33.00
4.00
3.00
6

About BLIS Technologies

View Profile
Address
81 Glasgow Street
Dunedin OT 9012
New Zealand
Employees -
Website http://www.blis.co.nz
Updated 07/08/2019
BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce Bacteriocin activity. It operates in the following geographical areas: Australasia, Asia (including China), Europe, and North America. The company was founded in June 2000 and is headquartered in Dunedin, New Zealand.